960155-98-0Relevant academic research and scientific papers
Synthesis, characterization and antitumor evaluation of CMCS-DTX conjugates as novel delivery platform for docetaxel
Liu, Fengxi,Feng, Lixia,Zhang, Li,Zhang, Xu,Zhang, Na
, p. 41 - 49 (2013)
The purpose of this study is to synthesis and evaluate the antitumor efficacy of a novel carboxymethyl chitosan-docetaxel (CMCS-DTX) conjugates and the availability of CMCS as the polymer material in polymer-drug conjugates development. Docetaxel (DTX) wa
Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin
Kim, Hyungjun,Lee, Yonghyun,Lee, In-Hyun,Kim, Sunghyun,Kim, Daejin,Saw, Phei Er,Lee, Jinju,Choi, Minsuk,Kim, Yong-Chul,Jon, Sangyong
, p. 118 - 124 (2014)
Targeted delivery of anticancer drugs to tumors has attracted considerable research interest because of its potential to reduce adverse toxicity while improving therapeutic efficacy. In this study, we synthesized and evaluated the therapeutic efficacy of
Synthetic copolymer conjugates of docetaxel and: In vitro assessment of anticancer efficacy
Boyer, Cyrille A.,Clemons, Tristan D.,Edwards, Sky,Evans, Cameron W.,Iyer, K. Swaminathan,Kretzmann, Jessica A.,Nealon, Gareth L.,Norret, Marck,Singh, Ruhani
supporting information, p. 20013 - 20020 (2020/12/21)
Docetaxel (DTX) is a widely used chemotherapy drug that is associated with numerous side effects and limited bioavailability. Macromolecular conjugates of DTX may improve drug targeting, solubility, reduce off-target toxicity, and overcome mechanisms of m
METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY
-
Paragraph 0083, (2020/12/30)
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X1 X2X3
Micro-molecule modified taxane water soluble prodrug and pharmaceutical applications thereof
-
Paragraph 0034; 0035; 0036, (2019/03/26)
The invention belongs to the field of biomedicine, and relates to a micro-molecule modified taxane water soluble prodrug and pharmaceutical applications thereof. The invention provides a micro-molecule modified taxane water soluble prodrug represented by
Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis
Wen, Xiaoming,Zheng, Purong,Ma, Yao,Ou, Yingye,Huang, Weixin,Li, Shuo,Liu, Shoujia,Zhang, Xuan,Wang, Ziyu,Zhang, Qianli,Cheng, Wenming,Lin, Ruwen,Li, Hongzu,Cai, Youyou,Hu, Chunyun,Wu, Ningbin,Wan, Long,Pan, Tingting,Rao, Jinlong,Bei, Xuelu,Wu, Weibin,Jin, Jian,Yan, Jie,Liu, Gang
, p. 1519 - 1540 (2018/03/05)
Salutaxel (3) is a conjugate of docetaxel (7) and a muramyl dipeptide (MDP) analogue. Docetaxel (7) has been recognized as a highly active chemotherapeutic agent against various cancers. MDP and its analogues are powerful potentiators of the antitumor act
Anti-tumor medicine conjugate, preparation method, preparation and application
-
Paragraph 0070; 0071; 0072; 0073; 0074; 0075, (2017/06/10)
The invention discloses an anti-tumor medicine conjugate, a preparation method, nano-micelle preparation thereof and application. The structural formula of the conjugate provided by the invention is represented by the formula (I), and the conjugate is for
Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations
Wang, Hangxiang,Chen, Jianmei,Xu, Chang,Shi, Linlin,Tayier, Munire,Zhou, Jiahui,Zhang, Jun,Wu, Jiaping,Ye, Zhijian,Fang, Tao,Han, Weidong
, (2017/09/05)
Abstract Combination therapy using distinct mode-of-action drugs has sparked a rapidly growing interest because this paradigm holds promise for improving the therapeutic efficacy of anticancer therapy. However, the current drug combination therapy refers
TARGETED THERAPEUTICS
-
Paragraph 002106, (2015/03/28)
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
Drug-initiated, controlled ring-opening polymerization for the synthesis of polymer-drug conjugates
Tong, Rong,Cheng, Jianjun
experimental part, p. 2225 - 2232 (2012/06/18)
Paclitaxel, a polyol chemotherapeutic agent, was covalently conjugated through its 2′-OH to polylactide with 100% regioselectivity via controlled polymerization of lactide mediated by paclitaxel/(BDI-II)ZnN(TMS)2 (BDI-II = 2-((2,6-diisopropylph
